Login / Signup

No benefit from flexible titration above minimum licensed dose in prescribing antidepressants for major depression: systematic review.

Toshiaki A FurawakaG SalantiP J CowenS LeuchtA Cipriani
Published in: Acta psychiatrica Scandinavica (2020)
There was no evidence to support added value in terms of efficacy, tolerability or acceptability of flexibly titrating up the dosage over the minimum licensed dose of SSRIs or mirtazapine. For venlafaxine, increased efficacy can be expected by flexibly titrating up to 150 mg.
Keyphrases
  • systematic review
  • meta analyses
  • major depressive disorder
  • open label
  • randomized controlled trial
  • clinical trial
  • placebo controlled